NCT02104336View on ClinicalTrials.gov

Phase 2 Study of EPI-743 in Children With Pearson Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

February 29, 2016

Conditions
Pearson Syndrome
Interventions
DRUG

EPI-743

EPI-743 is the quinone oxidation product of alpha-tocotrienol

Trial Locations (4)

15224

Children's Hospital of Pittsburgh, Pittsburgh

77030

Baylor College of Medicine, Houston

82868

Children's Hospital of Orange County, Orange

Unknown

Cleveland Clinic, Cleveland

Sponsors
All Listed Sponsors
lead

Edison Pharmaceuticals Inc

INDUSTRY